FDA Grants Priority Review for ENHERTU Supplement Application
The FDA has granted priority review status for the supplemental application of ENHERTU (BLA761139) by Daiichi Sankyo.
Therapeutic Area
Therapeutic area intelligence for HER2-Targeted Therapy with 1 indexed intelligence signal across regulatory, clinical, competitive, and market developments.
No related entities indexed yet.
No catalysts indexed for this entity yet.
No related entities indexed yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.